Article-3
MEDICAL NEWS HEADLINE:
NOT ALL ARGININE FORMULAS DELIVER NITRIC OXIDE (NO) TO CANCER CELL SITES

PRESS RELEASE PATENT ISSUED IN THE TRANSPORT OF NO MOLECULE, L-ARGININE IN HUMANS MEDICAL NEWS HEADLINE: NOT ALL ARGININE FORMULAS DELIVER NITRIC OXIDE (NO) TO CANCER CELL SITES January 2004 In the treatment of cancer, there has been a great deal of interest in developing techniques that are capable of opening the blood-brain barrier to allow transport of anti-cancer agents to the brain for use in the entire human body. The blood-brain barrier is a transvascularpermeability barrier which is a result of the interendothelial tight junctions formed by cerebrovascular endothelial cells of brain capillaries and arterioles in brain tissues. It is known that few methodologies and techniques allow transport of anti-cancer agents to selectively open the blood-brain barrier in humans while leaving the barrier in normal brain tissue intact. This has been a significant issue in utilizing anti-tumor agents, such as nitric oxide (NO) in the treatment of human cancers. NO is known to play a significant role in anti-tumor activity in humans and an important role in the regulation of the blood-brain barrier. It is evidenced that NO can activate the calcium-activated potassium channel (Kca) by both cGMP-dependent and independent mechanisms. In order for this to occur, L-arginine, the sole NO molecule in the human body, must be allowed to cross the blood-brain barrier uninhibited so NO can be transported to specific sites for anti-tumor activity. This delicate mechanism has remained a mystery in medical science until recently. Following a twenty-year development period, a Patent has been issued to Dr. Ann de Wees Allen for an L-arginine compound that allows transport of L-arginine across the blood-brain barrier for production of growth hormone (GH) anti-aging hormone, and nitric oxide (NO). Dr. Allen's L-arginine formula utilizes a low glycemic base of Trutina Dulcem and non-competing amino acids developed under proprietary conditions. The specific formula prevents brain-hypoglycemia from blunting NO and GH produced via oral ingestion of large amounts of elemental L-arginine, and allows production of NO and GH without any side effects, thus allowing complete blood-brain barrier cross over. L-arginine formulas that contain sucrose, sugars, maltodextrins, and other sweetening agents have been shown in clinical studies to blunt nitric oxide (NO) and GH. Serious side effects related to excess NO and GH are evidenced in many L-arginine, nitric oxide, and growth hormone formulas currently on the market. When asked to comment on these "rogue products," Dr. Allen stated, "It's quite disturbing to see L-arginine and nitric oxide products popping into the market that have virtually no history of safe use and no science related to the development of the product." "You cannot simply take L-arginine and produce a valid product. It takes years of research." Dr. Ann de Wees Allen's patents have been named "Breakthrough Product of the Year" by Success magazine and have been featured on the front page of the Wall Street Journal. She is named in the Who's Who of Inventors and Diabetes Educators. Her patents, CV, and arginine research projects may be seen at www.arginineresearch.com end report